Medical Prevention Therapy
Conditions
Brief summary
Primary Objective: \- To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings. Secondary Objective: * To describe the demographic and clinical characteristics of patients with symptomatic VTE including characteristics of VTE, VTE risk factors and bleeding risk factors. * To assess the frequency of patient characteristics that would necessitate adjustment in the dose or duration of enoxaparin therapy, e.g. high BMI, impaired creatinine clearance, advanced age, cancer-associated VTE. * To assess the degree of adherence in clinical practice to Consensus Guidelines (ACCP/American College of chest Physician 2008) for the management of acute VTE, vis a vis: * Appropriate dosing of enoxaparin * Recommended duration of initial LMWH therapy * Adequate overlap of LMWH with vitamin K antagonists (VKA) * Recommended duration of longterm VKA * Frequency of use of LMWH monotherapy to treat cancer-related VTE * To access safety outcomes (including bleeding and recurrent VTE) * To describe the utilization of resources due to bleeding and recurrent VTE during the treatment period.
Interventions
None listed
Sponsors
Sanofi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Objectively confirmed VTE * Initiation of enoxaparin treatment within Day 0-10 after diagnosis of VTE: * Outpatients who will be treated with enoxaparin + VKA in combination are permitted to receive initial treatment other than enoxaparin for a maximum of 48 hours or 2 treatment doses preceding entry into the study * Outpatients on enoxaparin monotherapy are permitted to receive up to 10 days of treatment other than enoxaparin preceding entry into the study.
Exclusion criteria
\- Medical or psychiatric disorders associated with altered cognition or mentation that precludes understanding of the informed consent process. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of exnoxaparin prefilled syringes vs. multidose vials used during treatment | Day 180 or end of anticoagulant therapy whichever comes first |
| Proportion of patients with Deep Venous Thrombosis (DVT) and/or Pulmonary Embolism (PE) and/or thrombosis at unusual sites | Day 180 or end of anticoagulant therapy whichever comes first |
| Number of patients prescribed twice daily (BID) vs. once daily (QD) enoxaparin | Day 180 or end of anticoagulant therapy whichever comes first |
| Proportion of patients who used short (5-7 days) vs. longer use (more than 7 days) durations of treatment with enoxaparin | Day 180 or end of anticoagulant therapy whichever comes first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient characteristics associated with different patterns of VTE management and enoxaparin use | Day 180 or end of anticoagulant therapy whichever comes first | Analysis of patient characteristics associated with different patterns of VTE management and enoxaparin use, such as age, weight, creatinine clearance, co-morbid disease, VTE characteristics, concomitant use of other pharmacological and non-pharmacological treatment of the VTE, concomitant use of other non-VTE related therapies |
| Percentage of cases managed as recommended by Concensus Guidelines (ACCP 2008) | Day 180 or end of anticoagulant therapy whichever comes first | — |
| Incidence of bleeding events and episodes of recurrent VTE | Day 180 or end of anticoagulant therapy whichever comes first | — |
| To tabulate VTE-related resources utilized during the study period and compare resource utilization in patients treated vs not treated as per Concensus Guidelines (ACCP 2008) | Day 180 or end of anticoagulant therapy whichever comes first | VTE-related resources utilized during the study period, including cost of VTE and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions, costs of recurrent VTE) and compare resource utilization in patients treated vs. not treated as recommended by Concensus Guidelines (ACCP 2008) |
Countries
Canada
Outcome results
None listed